1
|
Luu DV, Tran TH, Nguyen DH, Luong LH, Bui HTT, Nguyen MT, Ta MH, Tran VK, Bui TH, Ta TV. Mutation characteristic of 103 haemophilia A patients in Vietnam: Identification of novel mutations. Haemophilia 2019; 25:e274-e277. [PMID: 30913330 DOI: 10.1111/hae.13738] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2018] [Revised: 02/14/2019] [Accepted: 02/21/2019] [Indexed: 06/09/2023]
Affiliation(s)
| | - Thinh Huy Tran
- Hanoi Medical University, Hanoi, Vietnam
- Hanoi Medical University Hospital, Hanoi, Vietnam
| | - Duc Hinh Nguyen
- Hanoi Medical University, Hanoi, Vietnam
- Hanoi Medical University Hospital, Hanoi, Vietnam
| | | | | | - Mai Thi Nguyen
- National Institute of Hematology and Blood Transfusion, Hanoi, Vietnam
| | | | | | - The-Hung Bui
- Hanoi Medical University, Hanoi, Vietnam
- Clinical Genetics Unit, Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - Thanh Van Ta
- Hanoi Medical University, Hanoi, Vietnam
- Hanoi Medical University Hospital, Hanoi, Vietnam
| |
Collapse
|
2
|
Luna-Záizar H, González-Alcázar JÁ, Evangelista-Castro N, Aguilar-López LB, Ruiz-Quezada SL, Beltrán-Miranda CP, Jaloma-Cruz AR. F8 inversions of introns 22 and 1 confer a moderate risk of inhibitors in Mexican patients with severe hemophilia A. Concordance analysis and literature review. Blood Cells Mol Dis 2018; 71:45-52. [PMID: 29544691 DOI: 10.1016/j.bcmd.2018.02.003] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2018] [Accepted: 02/22/2018] [Indexed: 01/02/2023]
Abstract
Intron-22 (Inv22) and intron-1 (Inv1) inversions account for approximately one half of all severe cases of hemophilia A (SHA) worldwide. Inhibitor development against exogenous factor VIII (FVIII) represents a major complication in HA. The causative F8 mutation is considered the most decisive factor conditioning inhibitor development. We aimed to investigate prevalence of Inv22 and Inv1 mutations, and its association as risk factors for developing inhibitors to FVIII. We investigated Inv22 and Inv1 in 255 SHA Mexican patients from 193 unrelated families using the inverse shifting-polymerase chain reaction (IS-PCR). We analyzed the association between inversions and inhibitor development via logistic regression introducing as covariates the populations, the inversions, F8-haplotypes and the age of patients at enrollment. Inv22 was found in 91/193 (47.2%: 38.9% exhibited Inv22-1 and 8.3% Inv22-2), and Inv1 in 2/193 (1.0%) independent families. Absolute inhibitor prevalence (IP) for Inv22 in unrelated patients was 15% (10-19). The cohorts and age of patients were independent predictors of inhibitor risk, but not inversions or haplotypes. Inversions presence in our population was associated to a moderate risk of developing inhibitors. Inv1 was found for the first time in two Mexican families. A relevant genetic component was observed by the strong concordance among brother-pairs.
Collapse
Affiliation(s)
- Hilda Luna-Záizar
- Departamento de Química, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.
| | - José Ángel González-Alcázar
- Departamento de Química, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
| | - Natalia Evangelista-Castro
- Departamento de Química, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
| | - Lilia Beatriz Aguilar-López
- UMAE Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, Mexico
| | - Sandra Luz Ruiz-Quezada
- Departamento de Química, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
| | | | - Ana Rebeca Jaloma-Cruz
- División de Genética, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, Mexico.
| |
Collapse
|
3
|
D'Argenio V. The High-Throughput Analyses Era: Are We Ready for the Data Struggle? High Throughput 2018; 7:E8. [PMID: 29498666 PMCID: PMC5876534 DOI: 10.3390/ht7010008] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2017] [Revised: 02/16/2018] [Accepted: 02/27/2018] [Indexed: 12/23/2022] Open
Abstract
Recent and rapid technological advances in molecular sciences have dramatically increased the ability to carry out high-throughput studies characterized by big data production. This, in turn, led to the consequent negative effect of highlighting the presence of a gap between data yield and their analysis. Indeed, big data management is becoming an increasingly important aspect of many fields of molecular research including the study of human diseases. Now, the challenge is to identify, within the huge amount of data obtained, that which is of clinical relevance. In this context, issues related to data interpretation, sharing and storage need to be assessed and standardized. Once this is achieved, the integration of data from different -omic approaches will improve the diagnosis, monitoring and therapy of diseases by allowing the identification of novel, potentially actionably biomarkers in view of personalized medicine.
Collapse
Affiliation(s)
- Valeria D'Argenio
- CEINGE-Biotecnologie Avanzate, via G. Salvatore 486, 80145 Naples, Italy.
- Department of Molecular Medicine and Medical Biotechnologies, University of Naples Federico II, via Pansini 5, 80131 Naples, Italy.
| |
Collapse
|
4
|
Haemophilia A: the consequences of de novo mutations. Two case reports. BLOOD TRANSFUSION = TRASFUSIONE DEL SANGUE 2017; 16:392-393. [PMID: 28488976 DOI: 10.2450/2017.0292-16] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Subscribe] [Scholar Register] [Received: 10/17/2016] [Accepted: 11/09/2016] [Indexed: 01/19/2023]
|
5
|
Bury L, Nardiello P, Fierro T, Zarrilli F, Coppola A, Castaldo G, Gresele P. First Diagnosis of Hemophilia B in a Nonagenarian. J Am Geriatr Soc 2016; 64:230-1. [PMID: 26782891 DOI: 10.1111/jgs.13898] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Loredana Bury
- Department of Medicine, Section of Internal and Cardiovascular Medicine, Università di Perugia, Perugia, Italy
| | | | - Tiziana Fierro
- Department of Medicine, Section of Internal and Cardiovascular Medicine, Università di Perugia, Perugia, Italy
| | - Federica Zarrilli
- Department of Bioscience and Territory, Università del Molise, Isernia, Italy
| | - Antonio Coppola
- Department of Clinical Medicine and Surgery, Regional Reference Center for Emocoagulopatie, Università di Napoli Federico II, Naples, Italy
| | - Giuseppe Castaldo
- CEINGE-Biotecnologie Avanzate scarl, Naples, Italy.,Department of Molecular Medicine and Medical Biotechnology, Università di Napoli Federico II, Naples, Italy
| | - Paolo Gresele
- Department of Medicine, Section of Internal and Cardiovascular Medicine, Università di Perugia, Perugia, Italy
| |
Collapse
|
6
|
Nougier C, Roualdes O, Fretigny M, d'Oiron R, Costa C, Negrier C, Vinciguerra C. Characterization of four novel molecular changes in the promoter region of the factor VIII gene. Haemophilia 2013; 20:e149-56. [DOI: 10.1111/hae.12346] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/17/2013] [Indexed: 01/10/2023]
Affiliation(s)
- C. Nougier
- Service d'Hématologie Biologique; HCL, Hôpital Edouard Herriot; Lyon France
- EAM 4174 Hémostase, Inflammation et Sepsis; Université Claude Bernard Lyon 1; Lyon France
| | - O. Roualdes
- Service d'Hématologie Biologique; HCL, Hôpital Edouard Herriot; Lyon France
- EAM 4174 Hémostase, Inflammation et Sepsis; Université Claude Bernard Lyon 1; Lyon France
| | - M. Fretigny
- Service d'Hématologie Biologique; HCL, Hôpital Edouard Herriot; Lyon France
| | - R. d'Oiron
- Centre de Traitement pour Hémophiles, AP-HP Hôpital Bicêtre; Université Paris XI; le Kremlin-Bicêtre France
| | - C. Costa
- Département de Génétique; CHU Henri Mondor-AP-HP; Créteil France
| | - C. Negrier
- Service d'Hématologie Biologique; HCL, Hôpital Edouard Herriot; Lyon France
- EAM 4174 Hémostase, Inflammation et Sepsis; Université Claude Bernard Lyon 1; Lyon France
| | - C. Vinciguerra
- Service d'Hématologie Biologique; HCL, Hôpital Edouard Herriot; Lyon France
- EAM 4174 Hémostase, Inflammation et Sepsis; Université Claude Bernard Lyon 1; Lyon France
| |
Collapse
|
7
|
Castaldo G, Scorza M, Elce A, Giordano S, Liguori R, Guerra G. Omics in laboratory medicine. J Matern Fetal Neonatal Med 2013; 26 Suppl 2:13-6. [DOI: 10.3109/14767058.2013.829694] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
8
|
Sanna V, Ceglia C, Tarsitano M, Lombardo B, Coppola A, Zarrilli F, Castaldo G, Di Minno G. Aberrant F8 gene intron 1 inversion with concomitant duplication and deletion in a severe hemophilia A patient from Southern Italy. J Thromb Haemost 2013; 11:195-7. [PMID: 23140572 DOI: 10.1111/jth.12061] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- V Sanna
- CEINGE-Biotecnologie Avanzate, Naples Dipartimento di Biochimica e Biotecnologie Mediche, Università degli Studi di Napoli "Federico II", Naples, Italy
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Zarrilli F, Sanna V, Ingino R, Santamaria R, Rocino A, Coppola A, Di Minno G, Castaldo G. Prenatal diagnosis of haemophilia: our experience of 44 cases. Clin Chem Lab Med 2013; 51:2233-8. [DOI: 10.1515/cclm-2013-0205] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2012] [Accepted: 03/08/2013] [Indexed: 11/15/2022]
|
10
|
F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood 2012; 119:2922-34. [PMID: 22282501 DOI: 10.1182/blood-2011-09-379453] [Citation(s) in RCA: 252] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
This systematic review was designed to provide more precise effect estimates of inhibitor development for the various types of F8 gene mutations in patients with severe hemophilia A. The primary outcome was inhibitor development and the secondary outcome was high-titer-inhibitor development. A systematic literature search was performed to include cohort studies published in peer-reviewed journals with data on inhibitor incidences in the various F8 gene mutation types and a mutation detection rate of at least 80%. Pooled odds ratios (ORs) of inhibitor development for different types of F8 gene mutations were calculated with intron 22 inversion as the reference. Data were included from 30 studies on 5383 patients, including 1029 inhibitor patients. The inhibitor risk in large deletions and nonsense mutations was higher than in intron 22 inversions (pooled OR = 3.6, 95% confidence interval [95% CI], 2.3-5.7 and OR = 1.4, 95% CI, 1.1-1.8, respectively), the risk in intron 1 inversions and splice-site mutations was equal (pooled OR = 0.9; 95% CI, 0.6-1.5 and OR = 1.0; 95% CI, 0.6-1.5), and the risk in small deletions/insertions and missense mutations was lower (pooled OR = 0.5; 95% CI, 0.4-0.6 and OR = 0.3; 95% CI, 0.2-0.4, respectively). The relative risks for developing high titer inhibitors were similar.
Collapse
|
11
|
Castaldo G, Lembo F, Tomaiuolo R. Molecular diagnostics: between chips and customized medicine. Clin Chem Lab Med 2010; 48:973-82. [PMID: 20441468 DOI: 10.1515/cclm.2010.182] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
Recently there has been an explosive increase in molecular diagnostics. This is due to translational research on the molecular basis of human diseases, and to technological developments that have resulted in efficient procedures for extensive analysis of the human genome. However, a large body of data on the genome is still difficult to interpret at the clinical level. For many monogenic diseases, "modifier" genes, inherited independently of the disease gene interact, thereby resulting in a distinct phenotype for each patient. Multigenic diseases depend on complex interactions between genes and the environment. Response to drugs and side effects are modulated by gene variants. The same is true for the response to nutrients. All these interactions, which vary from patient to patient, led to the concept of "personalized medicine". Our genome consists of 25,000 genes, a surprisingly low number when compared to other species. Therefore, the complex phenotype of humans depends on a number of mechanisms that regulate gene expression, which, in turn, may be altered resulting in disease. For example, DNA methylation modulates the level of gene expression, and altered methylation of some genes is related to human neoplasias. MicroRNAs regulate the expression of a myriad of genes, and mounting evidence indicates that this mechanism may be impaired in human diseases. Finally, the relationships between genetics and human behavior are starting to be elucidated. For example, suicide may be related to alterations of methylation of specific genes. To conclude: the chip-wide analysis of human genomes is becoming easier, but the understanding of molecular genetics that confirmed the real "uniqueness" of each genome is an excellent opportunity for laboratory medicine to reposition the patient at the heart of the medical process.
Collapse
|